Published in Mol Diagn Ther on April 01, 2010
Effectiveness of conventional drug therapy of plaque psoriasis in the context of consensus guidelines: a prospective observational study in 150 patients. Ann Dermatol (2013) 0.80
Dermatology: future therapeutic perspectives. Dermatol Ther (Heidelb) (2013) 0.75
Emerging therapies for the treatment of psoriasis. Dermatol Ther (Heidelb) (2012) 0.75
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol (2003) 1.60
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol (2004) 1.53
Cardiocutaneous syndromes and associations. J Am Acad Dermatol (2002) 1.53
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol (2007) 1.44
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol (2012) 1.40
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed (2005) 1.39
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol (2008) 1.28
The use of cyclosporine in dermatology: part I. J Am Acad Dermatol (2010) 1.26
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Comorbidities in psoriasis patients. Semin Cutan Med Surg (2010) 1.21
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol (2007) 1.17
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis (2003) 1.16
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 1.15
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (2008) 1.15
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol (2003) 1.09
The use of cyclosporine in dermatology: part II. J Am Acad Dermatol (2010) 1.07
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther (2003) 1.04
Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol (2004) 1.03
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol (2005) 1.01
Update on botulinum toxin for facial aesthetics. Dermatol Clin (2002) 1.01
Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol (2013) 0.98
Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis (2011) 0.96
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol (2003) 0.96
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol (2009) 0.96
Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol (2005) 0.96
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One (2011) 0.92
Psoriatic arthritis: an update. Arthritis (2012) 0.92
Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Ann Rheum Dis (2012) 0.91
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol (2013) 0.91
Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis (2002) 0.91
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) (2013) 0.90
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes (2008) 0.90
Treating moderate to severe psoriasis - best use of biologics. Expert Rev Clin Immunol (2013) 0.90
Psoriasis and the metabolic syndrome. J Drugs Dermatol (2008) 0.90
Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin (2012) 0.90
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol (2006) 0.89
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol (2004) 0.89
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat (2007) 0.88
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol (2013) 0.87
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Arch Dermatol Res (2013) 0.87
Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol (2012) 0.87
Current investigational drugs in psoriasis. Expert Opin Investig Drugs (2012) 0.86
Changing paradigms in dermatology: nuclear hormone receptors. Clin Dermatol (2003) 0.86
Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy. Clin Lymphoma Myeloma Leuk (2010) 0.86
Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol (2009) 0.86
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol (2008) 0.84
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol (2013) 0.84
Genetic susceptibility to psoriasis: an emerging picture. Genome Med (2009) 0.84
AAD consensus statement on psoriasis therapies. J Am Acad Dermatol (2003) 0.84
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol (2007) 0.83
Expression of microRNA-184 in keratinocytes represses argonaute 2. J Cell Physiol (2013) 0.83
Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. J Cosmet Laser Ther (2006) 0.83
Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol (2014) 0.83
Novel therapies for psoriasis. Am J Clin Dermatol (2002) 0.83
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res (Hoboken) (2014) 0.81
Topical treatment of psoriasis. Curr Probl Dermatol (2009) 0.81
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol (2002) 0.81
Ciclopirox gel in the treatment of patients with interdigital tinea pedis. Int J Dermatol (2003) 0.81
Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs (2013) 0.81
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol (2010) 0.80
No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. J Invest Dermatol (2008) 0.80
Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council. J Dermatolog Treat (2012) 0.80
Infliximab. Dermatol Ther (2004) 0.80
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology (2006) 0.79
Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol (2010) 0.79
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin (2010) 0.79
The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther (2010) 0.79
Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol (2009) 0.79
Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat (2015) 0.78